Protalix BioTherapeutics, Inc. Q3 2025 Earnings Recap

PLX Q3 2025 November 13, 2025

Get alerts when PLX reports next quarter

Protalix BioTherapeutics reported strong year-to-date revenue growth of 24%, though third-quarter revenues showed a slight decline of 1% compared to the previous year, reflecting ongoing inventory management by key partners.

Earnings Per Share Miss

$0.03 vs $0.06 est.

-50.0% surprise

Revenue Beat

17851000 vs 14244000 est.

+25.3% surprise

Market Reaction

1-Day -9.81%

5-Day -12.15%

30-Day -18.69%

See PLX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenues for the first nine months of 2025 reached $46.4 million, marking a 24% year-over-year increase.
Third-quarter revenue was $17.9 million, down 1% year-over-year due to variable inventory control by partners.
The company is advancing its PRX-115 candidate for the treatment of uncontrolled gout, having filed for a Phase 2 clinical trial.
Research and development expenses surged by 58% for the first nine months, emphasizing continued investment in pipeline projects.
Protalix maintains a strong cash position and positive net income, supporting its strategic focus on commercial success and innovation.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit PLX on AllInvestView.

Previous Q2 2025